Variable | Patients without MACE | Patients with MACE | p-value |
---|---|---|---|
Number of participants (n) | 155 | 45 | Â |
Age (yr) | 61 (52–70) | 69 (65–72) | < 0.001 |
Female sex (n, %) | 66 (42.6) | 9 (20.0) | 0.006 |
BMI | 28.7 (± 0.5) | 29.0 (± 0.9) | 0.770 |
Hypertension (n, %) | 138 (89.0) | 40 (88.9) | 0.978 |
Hypercholesterolemia (n, %) | 124 (80.0) | 39 (86.7) | 0.346 |
Diabetes (n, %) | 29 (18.7) | 19 (42.2) | 0.001 |
 - Type 1 diabetes (n, %)  - Type 2 diabetes (n, %) | 4 (2.6) 25 (16.1) | 2 (4.4) 17 (37.8) |  |
Prevalent CVD at baseline (n, %) | 21 (13.5) | 21 (46.7) | < 0.001 |
Smoking (pack years) | 3 (0–20) | 21 (0–50) | 0.006 |
Medication (n, %) | Â | Â | Â |
 - Anti-hypertensive  - Lipid-lowering  - Diabetic treatment  - Anti-platelet  - Anti-coagulation | 130 (83.9) 73 (47.1) 22 (14.2) 36 (23.2) 5 (3.2) | 38 (84.4) 31 (68.9) 17 (37.8) 26 (57.8) 4 (8.9) | 0.926 0.010 < 0.001 < 0.001 0.117 |
P-creatinine (µmol/l) | 138 (120–163) | 150 (132–169) | 0.048 |
eGFR (ml/min/1.73m2) | 41 (35–50) | 38 (34–44) | 0.039 |
P-HDL-cholesterol (mmol/l) | 1.53 (± 0.05) | 1.46 (± 0.09) | 0.460 |
P-LDL-cholesterol (mmol/l) | 3.0 (± 0.1) | 2.7 (± 0.1) | 0.073 |
P-triglycerides (mmol/l) | 1.51 (1.12–2.24) | 1.63 (1.28–2.51) | 0.318 |
P-glucose (mmol/l) | 6.1 (± 0.1) | 6.9 (± 0.3) | 0.017 |
P-ionized calcium (mmol/l) | 1.23 (± 0.00) | 1.20 (± 0.01) | 0.003 |
P-phosphate (mmol/l) | 1.02 (± 0.02) | 1.05 (± 0.03) | 0.454 |
P-urate (mmol/l) | 0.45 (± 0.01) | 0.44 (± 0.02) | 0.800 |
Urine albumin/creatinine ratio x 10− 3 | 56 (7-271) | 138 (35–692) | 0.016 |
Plaque presence at baseline (n, %) | 76 (49.0) | 39 (86.7) | < 0.001 |
cPTmax at baseline (mm) | 0 (0-1.6) | 1.9 (1.5–2.8) | < 0.001 |
CACS | 7 (0-156) | 370 (87-1044) | < 0.001 |
CACS categories (n, %): |  |  | < 0.001 |
No coronary calcification CACS 1-100 CACS 101–400 CACS > 400 | 66 (47.8) 30 (21.7) 21 (15.2) 21 (15.2) | 7 (18.9) 3 (8.1) 10 (27.0) 17 (45.9) |  |